ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Dendreon To Make Major Job Cuts

by Lisa M. Jarvis
August 6, 2012 | APPEARED IN VOLUME 90, ISSUE 32

Dendreon will cut 600 jobs, or roughly 40% of its workforce, and close its Morris Plains, N.J., manufacturing facility in an attempt to save roughly $150 million annually. Dendreon has struggled to become profitable since the 2010 approval of its prostate cancer immunotherapy, Provenge. Sales of Provenge totaled $80 million in the second quarter, down 2.4% from the first quarter, and the drug is expected to face fierce competition from new products in the coming months. Dendreon shed 500 workers in September 2011.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment